NASDAQ:MDXG - MiMedx Group Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $15.75
  • Forecasted Upside: 156.93 %
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$6.13
▼ -0.2 (-3.16%)

This chart shows the closing price for MDXG by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New MiMedx Group Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MDXG and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MDXG

Analyst Price Target is $15.75
▲ +156.93% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for MiMedx Group in the last 3 months. The average price target is $15.75, with a high forecast of $23.00 and a low forecast of $8.50. The average price target represents a 156.93% upside from the last price of $6.13.

This chart shows the closing price for MDXG for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 2 contributing investment analysts is to buy stock in MiMedx Group.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/6/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/5/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/3/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/1/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/1/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/30/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/29/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/28/2021

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
9/14/2021HC WainwrightLower Price TargetBuy$20.00 ➝ $8.50High
7/26/2021Northland SecuritiesInitiated CoverageOutperform$23.00Medium
3/19/2021HC WainwrightInitiated CoverageBuy$20.00High
3/15/2018Needham & Company LLCReiterated RatingHoldHigh
2/27/2018Craig HallumReiterated RatingBuyLow
2/23/2018Lake Street CapitalDowngradeBuy ➝ Hold$9.00Low
2/21/2018Lake Street CapitalSet Price TargetBuy$18.00 ➝ $12.00Low
2/20/2018Needham & Company LLCDowngradeStrong-Buy ➝ HoldHigh
12/14/2017Lake Street CapitalSet Price TargetBuy$18.00Low
12/1/2017Piper Jaffray CompaniesReiterated RatingBuy$18.00Low
12/1/2017Needham & Company LLCReiterated RatingBuy$21.00Low
11/24/2017Piper Jaffray CompaniesReiterated RatingBuy$18.00Medium
11/14/2017Needham & Company LLCReiterated RatingBuy$21.00N/A
10/30/2017Needham & Company LLCReiterated RatingBuy$21.00N/A
9/5/2017Needham & Company LLCBoost Price TargetStrong-Buy ➝ Strong-Buy$20.00 ➝ $21.00Low
8/20/2017Piper Jaffray CompaniesReiterated RatingBuy$18.00Low
8/3/2017Needham & Company LLCInitiated CoverageBuyMedium
7/30/2017Needham & Company LLCReiterated RatingStrong-Buy$20.00Medium
7/28/2017Lake Street CapitalBoost Price TargetBuy$16.00 ➝ $18.00High
6/26/2017Needham & Company LLCReiterated RatingBuy$15.00 ➝ $20.00Medium
5/23/2017First AnalysisDowngradeEqual Weight ➝ Underweight$11.00High
4/26/2017Needham & Company LLCReiterated RatingBuy$15.00High
4/13/2017Needham & Company LLCReiterated RatingBuy$12.00 ➝ $15.00High
3/3/2017Piper Jaffray CompaniesInitiated CoverageOverweight ➝ Overweight$10.00N/A
2/23/2017Needham & Company LLCReiterated RatingBuy$12.00N/A
12/21/2016Needham & Company LLCReiterated RatingStrong-Buy$12.00N/A
12/12/2016First AnalysisReiterated RatingHoldN/A
12/12/2016UBS GroupInitiated CoverageSell$9.00N/A
11/7/2016AegisInitiated CoverageBuy$12.00N/A
(Data available from 9/28/2016 forward)

News Sentiment Rating

0.22 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/2/2021
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/1/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/1/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/31/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/30/2021
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/30/2021
  • 2 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/29/2021
  • 2 very positive mentions
  • 13 positive mentions
  • 5 negative mentions
  • 0 very negative mentions
9/28/2021

Current Sentiment

  • 2 very positive mentions
  • 13 positive mentions
  • 5 negative mentions
  • 0 very negative mentions
MiMedx Group logo
MiMedx Group, Inc. is a therapeutic biologics company, which engages in the design, manufacture, and marketing of products, and tissue processing services. It serves the wound care, burn, surgical, orthopedic, spine, sports medicine, ophthalmic, and dental sectors of healthcare. Its biomaterial platform technologies include AmnioFix and EpiFix, a tissue allografts derived from amnion and chorion layers of human placental membrane; EpiCord and AmnioCord, a tissue allografts derived from umbilical cord tissue, and AmnioFill, a placental connective tissue matri derived from the placental disc and other placental tissue. The company was founded on July 30, 1985 and is headquartered in Marietta, GA.
Read More

Today's Range

Now: $6.13
Low: $6.07
High: $6.41

50 Day Range

MA: $11.57
Low: $5.52
High: $15.83

52 Week Range

Now: $6.13
Low: $5.30
High: $15.99

Volume

21,339 shs

Average Volume

823,723 shs

Market Capitalization

$686.25 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.65

Frequently Asked Questions

What sell-side analysts currently cover shares of MiMedx Group?

The following equities research analysts have issued reports on MiMedx Group in the last year: HC Wainwright, Northland Securities, and TheStreet.
View the latest analyst ratings for MDXG.

What is the current price target for MiMedx Group?

2 Wall Street analysts have set twelve-month price targets for MiMedx Group in the last year. Their average twelve-month price target is $15.75, suggesting a possible upside of 148.8%. Northland Securities has the highest price target set, predicting MDXG will reach $23.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $8.50 for MiMedx Group in the next year.
View the latest price targets for MDXG.

What is the current consensus analyst rating for MiMedx Group?

MiMedx Group currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe MDXG will outperform the market and that investors should add to their positions of MiMedx Group.
View the latest ratings for MDXG.

What other companies compete with MiMedx Group?

How do I contact MiMedx Group's investor relations team?

MiMedx Group's physical mailing address is 1775 W OAK COMMONS COURT NE, MARIETTA GA, 30062. The company's listed phone number is (770) 651-9100 and its investor relations email address is [email protected] The official website for MiMedx Group is www.mimedx.com.